Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT02933255 trial: what clinicians have said so far
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
- NCT02933255 ↗
- Completed
- National Cancer Institute (NCI)
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT02933255 (prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02933255 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- Phase I/II Study of PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Prostate Cancer
- Interventions
- PROSTVAC-V/F; Nivolumab; Prostatectomy; Biopsy; Tylenol
- Arms
- Lead-in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Cohort · Experimental
- Neoadjuvant Cohort · Experimental
- Enrollment
- 24
- Primary outcomes
- Number of Participants With Clinically Important Immune-related Adverse Events (for the Lead-In Cohort)
- Changes in T-cell Infiltration in the Tumor After Neoadjuvant Treatment (Only for the Neoadjuvant Cohort)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Apr 18, 2017
- Primary completion
- Jun 20, 2023
- Results posted
- Yes
- Registry record
- NCT02933255 · updated May 31, 2024
Publications
linked from the registry- Lassoued W, Madan RA, Xue E, Burnett D, Canubas KD, Bailey S, Marte JL, Tsai YT, Donahue RN, Turkbey IB, Papanicolau-Sengo A, Williams M, Hankin A, Manukyan M, Manu M, Kang Z, Pritchard C, Dahut W, Karzai F, Schlom J, Sater S, Pinto P, Gulley JL. Programmed death-1 inhibition increases vaccine-induced T-cell infiltration in patients with prostate cancer. J Immunother Cancer. 2025 Jun 22;13(6):e010851. doi: 10.1136/jitc-2024-010851. PubMed 40550568